Eli Lilly's New Weight-Loss Pill Shows Promising Results in Human Trials
TL;DR Summary
Eli Lilly's new weight loss pill, orforglipron, shows promising trial results with an average weight loss of 12.4% over 72 weeks, nearing the effectiveness of existing injections like Mounjaro and Wegovy. The pill could be easier and cheaper to produce and take, potentially making weight loss treatment more accessible through the NHS, although its efficacy is slightly lower than injectable options. Regulatory approval is anticipated soon, which could mark a significant advancement in obesity management.
- ‘Holy grail’ weight loss pill moves closer to NHS after staggering human trial results LADbible
- Lilly pill cuts body weight by 12.4% in trial, lagging Novo's Wegovy injection Reuters
- Daily oral GLP-1 pill could be just as effective as weekly shots: Drugmaker ABC News
- Lilly reports second-quarter 2025 financial results and raises guidance | Eli Lilly and Company Eli Lilly
- Eli Lilly Says Its New Weight-Loss Pill Is Highly Effective Time Magazine
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
3 min
vs 4 min read
Condensed
90%
723 → 75 words
Want the full story? Read the original article
Read on LADbible